LifebankUSA
 | This article's tone or style may not reflect the encyclopedic tone used on Wikipedia. (March 2014) (Learn how and when to remove this template message) |
LifebankUSA is a cord blood bank founded in 1998, located in Cedar Knolls, NJ, and is the only cord blood bank that enables parents to bank their newborn’s stem cells from two usable sources of stem cell-rich blood, the cord blood and the placenta. LifebankUSA also offers expectant parents the option of banking placenta tissue. Today, the company is only one of a few private cord blood banks that accepts cord blood donations. LifebankUSA is owned by Celgene Corporation, a multinational biopharmaceutical company committed to improving the lives of patients worldwide.[1]
Dr. Robert Hariri, Founder[edit]
Technological leaders in stem cell banking today, LifebankUSA was originally conceived as a result of the personal experience of its founder, Dr. Robert Hariri — neurosurgeon and stem cell pioneer.[2]
During a rotation in obstetrics at Cornell University Medical College, Dr. Hariri first became interested in the placenta, which provides nutrients and life-sustaining oxygen to the fetus. When he and his wife were about to become first-time parents, he was able to envision the potential of placental stem cells.
Dr. Hariri made it his mission to transform the potential of placental stem cells into a clinical reality. To fulfill his vision of collecting, processing, and preserving both cord blood and placenta-derived stem cells, he formed a company called Anthrogenesis. Later the company became LifebankUSA after being acquired by Celgene, an American biotechnology company. In 2007 and 2011, Dr. Hariri was awarded the Thomas Alva Edison Award for his achievements related to placental stem cell collection.
Cord & Placenta Blood Overview[edit]
Stem cells from cord and placenta blood have been shown to successfully replace abnormal or diseased cells and treat life-threatening blood disorders such as leukemia, lymphoma, and myeloma. Since 1988,cord blood stem cell transplants have been used to treat approximately 80 diseases.[3][4] Physicians have treated more than 25,000 patients worldwide with cord blood stem cells through a process called hematopoietic reconstitution (the reformation of blood cellular components).[5]
Only LifebankUSA is registered with the FDA to process the stem cells in both cord and placenta blood.[6] Compared to cord blood banking alone, placental & cord blood banking yields 41% more of a particular type of cell called a CD34+ stem cell.[7] Studies have shown that using more CD34+ stem cells can lead to a significant survival advantage in transplant patients.[8][9][10][11] [12] [13]
LifebankUSA client Quentin Murray was the first person in the world to receive a stem cell transplant from the cord and placenta blood. He was infused with his little sister’s cord and placenta blood stem cells. His cancer has been in complete remission since his transplant surgery, and he was deemed fully cured* on March 28, 2010, which marked the 2-year anniversary of his transplant.
Banking & Regenerative Medicine[edit]
In the years ahead, having more cells available through placental and cord blood banking may prove beneficial for new treatments in an emerging medical field known as regenerative medicine.[14][15] This pioneering medical approach involves repairing or replacing damaged tissues and organs that have been affected by congenital defects, disease, trauma, or aging, and restoring their critical functions.*,[16][17]
Specific stem cells called mesenchymal cells may prove useful for regenerative medicine treatments. Placental and cord blood contain mesenchymal-like cells. In laboratories, scientists have learned that mesenchymal stem cells have strong potential to repair bones and regrow cartilage.[18]
According to estimates, regenerative medicine could revolutionize health care, providing effective therapies for previously untreatable diseases and conditions. The US Department of Health and Human Services expects regenerative medicine to make significant advances over the next 10 to 20 years.[19]
References[edit]
- ↑ "Our Products—Celgene FDA-Approved Therapy".
- ↑ Regenerative Medicine: A Fundamental Shift in Science and Culture. Second International Conference. Robert Joseph Hariri, M.D., Ph.D., Speaker bio.. Accessed Dec. 3, 2013
- ↑ The Leukemia & Lymphoma Society. Cord blood stem cell transplantation. No. 2. Accessed Oct 15, 2013
- ↑ St. Jude Children's Research Hospital. Diseases treated by stem cell transplant. St. Jude Children's Research Hospital. Diseases treated by stem cell transplant. Accessed Oct 15, 2013
- ↑ Rocha V, Gluckman E; Eurocord-Netcord registry and European Blood and Marrow Transplant group. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft-and-transplantation-related factors. Br J Haematol. 2009;147(2):262-274
- ↑ Celgene Cellular Therapeutics Strengthens Intellectual Property Estate in the Field of Placental-Derived Stem Cells. May 16, 2006. Accessed Dec. 3, 2013
- ↑ Data on file A, LifebankUSA; 2010.
- ↑ Scaradavou A, on behalf of the National Cord Blood Program. Unrelated umbilical cord blood unit selection. Semin Hematol.47:13-21.
- ↑ Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611-1618.
- ↑ Cairo MS, Wagner EL, Fraser J, et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion. 2005;45(6):856-866.
- ↑ Styczynski J, Cheung Y-K, Garvin J, et al. Unrelated donor transplants: outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004;34(2):129-136
- ↑ Effect of CD34+ cells on survival
- ↑ Gluckman E, Rocha V. Donor selection for unrelated cord blood transplants. Curr Opin Immunol. 2006;18(5):565-570.
- ↑ US Department of Health and Human Services. 2020: a new vision-a future for regenerative medicine. Accessed Oct 15, 2013.
- ↑ Harris DT. Cord blood stem cells: a review of potential neurological applications. Stem Cell Rev. 2008;4(4):269-274.
- ↑ Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3(1):1-5.
- ↑ US Department of Health and Human Services. 2020: a new vision-a future for regenerative medicine. Accessed Oct 15, 2013.
- ↑ da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008;26(9):2287-2299.
- ↑ US Department of Health and Human Services. 2020: a new vision-a future for regenerative medicine. Accessed Oct 15, 2013.
This article "LifebankUSA" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
